Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate
about
sameAs
When prostate cancer remains undetectable: The dilemmaIdentification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment.Shear wave elastography for detection of prostate cancer: a preliminary study.Standards for prostate biopsy.Multiparametric MRI in the PSA screening eraWhole prostate volume and shape changes with the use of an inflatable and flexible endorectal coilProgensa PCA3 test for prostate cancer detection.Beyond diagnosis: evolving prostate biopsy in the era of focal therapy.Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.Prostate biopsy and anaesthesia: an overview.Saturation biopsy for detecting and characterizing prostate cancer.Epigenetic alterations in human prostate cancers.Effect of the number of biopsy cores on prostate cancer detection and staging.Epstein criteria for insignificant prostate cancer.Management of rising prostate-specific antigen after a negative biopsy.Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience.Prostate saturation biopsy following a first negative biopsy: state of the art.Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.Optimization of prostate biopsy: review of technique and complications.Random biopsy: when, how many and where to take the cores?Low risk patients benefit from extreme anterior apical sampling on initial biopsy for prostate cancer diagnosis.Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results.Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores.The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancerGleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy.Computerized transrectal ultrasound of the prostate in a multicenter setup (C-TRUS-MS): detection of cancer after multiple negative systematic random and in primary biopsies.Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme.High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.Ten-core versus 16-core transrectal ultrasonography guided prostate biopsy for detection of prostatic carcinoma: a prospective comparative study in Indian population.Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners.Hemosepermia after transrectal ultrasound-guided prostatic biopsy: A prospective study.High cancer detection rate using cognitive fusion - targeted transperineal prostate biopsiesOptimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume.Preliminary study on ultrasound-guided prostate biopsy specimen scoresFrequent DNA Hypermethylation at the RASSF1A and APC Gene Loci in Prostate Cancer Patients of Pakistani Origin.Contemporary pathologic characteristics and oncologic outcomes of prostate cancers missed by 6- and 12-core biopsy and diagnosed with a 21-core biopsy protocol.High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance.Application of transrectal ultrasound-guided repeat needle biopsy in the diagnosis of prostate cancer in Chinese population: A retrospective study.Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.Patient selection and pathological outcomes using currently available active surveillance criteria.
P2860
Q26795515-4074E5AD-4F72-4BDC-9CCC-3EBBD63D132FQ33592442-5B9F9C1B-F842-488A-8775-41A2C4D28DF6Q33620198-DA7154E1-CD0F-4D91-B394-A0B7BC00E284Q34079923-7E379848-5324-49B0-B1E0-C8A5C59AABC3Q34177428-D11E0237-CA98-4860-8327-C0B60A8BE9CBQ34412631-1B7BEC1D-D3AE-486B-A65E-8A1721443EC7Q34692442-56455B5C-AAFB-4356-81F5-5012E69AC817Q35550202-E7E7D61C-1ADE-4BD2-AA5A-0BEE476B0BE0Q35940184-6BDBE75A-D0BD-4109-84E8-2BD6B7D24C4FQ36194992-9523B634-6026-4DE0-AED0-1B651B57053EQ36788576-7951E421-656C-49F8-B3B0-378D9B63155AQ37328845-664E26B2-421A-446D-B1EF-8BF65799216FQ37707378-271DD3C2-A998-4FE5-8278-C6584185FD7FQ37841742-502C3D8F-BAF8-4376-9DFA-9AD8857E653CQ37846119-90AB84E3-6AAC-437C-B69C-A4E0B462F029Q37892629-EDBB1134-E76A-4C3D-8F50-F3DEF126DD04Q38027698-146CCCF7-AE19-4309-8729-2866760D0F4FQ38088877-E4885C51-60F5-448D-8A91-211BBC95B409Q38203986-B74248DA-9DC9-4437-917C-9B8686BB0506Q38218443-A2C67D2C-FC55-44F9-AAFC-A5740A350D67Q38222963-F25CA2FA-25AA-4F8B-9203-072A15097D43Q38573757-44CE79CF-BB5F-42D1-9430-CE046992CBCBQ39744064-FBD1A003-D867-49B6-A2F7-A53AF9A51316Q39803711-32F0617A-67FF-44A2-AC76-6D4BFB435FEAQ39947142-0EC4B3B8-FF6D-4299-BEAC-6BECCD90F299Q39987974-039E7CB9-7485-4A71-BB07-D0A49896B6FDQ40010533-992773D0-504F-41E5-A04D-5407143DC660Q40025070-1F7A76BD-123A-4416-AC73-7E3C28EC9729Q40162083-CD9D2A21-045F-476F-A7D4-9DDBEF8492BEQ40170080-5EC85DA9-D9F2-47CF-B65C-013B0DB9EA86Q40358364-A55EA83B-6AAF-4F8E-9D25-44BE2ACD7F18Q41412002-D6E98AD7-87A4-4CA7-98D7-731ECCA7E006Q41625821-72ACBD6B-DA6E-40AC-B0A9-1425B3DC92EBQ41672175-70831C98-F8BE-4607-9081-A150C9BC3694Q41845384-C1E66A8C-87DE-4326-B5FF-233F1708605FQ41901097-27EAD437-A788-4D7A-A0CD-E3A9D8555A9EQ42097270-A545809E-4D98-431C-8498-897F23625CE0Q42363869-79601810-0FCF-43A5-BA31-1980B6C8B8C3Q43431647-325EEF18-89D7-4623-9AD1-0BE28F1D492FQ43756470-3AB046BC-3060-4C00-8AB9-1063E874DAE4
P2860
Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Prospective evaluation of a 21 ...... prostate cancer detection rate
@ast
Prospective evaluation of a 21 ...... prostate cancer detection rate
@en
Prospective evaluation of a 21 ...... prostate cancer detection rate
@nl
type
label
Prospective evaluation of a 21 ...... prostate cancer detection rate
@ast
Prospective evaluation of a 21 ...... prostate cancer detection rate
@en
Prospective evaluation of a 21 ...... prostate cancer detection rate
@nl
prefLabel
Prospective evaluation of a 21 ...... prostate cancer detection rate
@ast
Prospective evaluation of a 21 ...... prostate cancer detection rate
@en
Prospective evaluation of a 21 ...... prostate cancer detection rate
@nl
P2093
P3181
P1433
P1476
Prospective evaluation of a 21 ...... prostate cancer detection rate
@en
P2093
Alexandre de la Taille
Andras Hoznek
Anthony Cicco
Claude Clément Abbou
Dimitri Vordos
Dominique Chopin
Elie Serge Zafrani
Fabien Saint
Laurent Salomon
Maguy Cherfan
P304
P3181
P356
10.1016/S0090-4295(03)00108-0
P407
P577
2003-06-01T00:00:00Z